Actorise 100 Injection (Darbepoetin Alfa)
Price range: $236.25 through $621.89Required
| Pack Size | Price | Unit Price | Quantity | |
|---|---|---|---|---|
| 2 Injection | $236.25 | $118.13 / injection | ||
| 4 Injection | $435.26 | $108.82 / injection | ||
| 6 Injection | $621.89 | $103.65 / injection |
About Actorise 100 Injection (Darbepoetin Alfa)
Medicine information
- Active ingredient
- Darbepoetin alfa
- Indication
- Treatment of anemia associated with chronic kidney disease; darbepoetin alfa is also used for anemia caused by concomitant myelosuppressive chemotherapy in selected patients with non-myeloid cancer. Actorise was originally launched in India specifically for anemia caused by chronic kidney disease.
- Manufacturer
- Cipla Ltd.
- Packaging
- 1 × 0.5 mL pre-filled syringe containing darbepoetin alfa 100 mcg.
- Strength
- 100 mcg
- Dosage form
- Injection, solution in pre-filled syringe
- Route
- Subcutaneous or intravenous
Medicine overview
Actorise 100 Injection contains 100 mcg of darbepoetin alfa in a 0.5 mL pre-filled syringe. It is an erythropoiesis-stimulating agent (ESA), a medicine that acts like the natural hormone erythropoietin and encourages bone marrow to produce red blood cells. Actorise is used to manage certain types of anemia, particularly anemia associated with chronic kidney disease. Darbepoetin alfa may also be used for chemotherapy-associated anemia in appropriately selected patients. Treatment requires regular monitoring of hemoglobin, blood pressure, iron status, and clinical response.
What it is used for
Actorise 100 Injection is used to increase red blood cell production in patients with appropriate forms of anemia. Its established use includes anemia associated with chronic kidney disease, including patients receiving dialysis and those not receiving dialysis. Darbepoetin alfa may also be used for anemia caused by myelosuppressive chemotherapy in selected patients with non-myeloid cancers when treatment meets the applicable prescribing criteria. It is not a substitute for a red blood cell transfusion when anemia requires immediate correction.
How it works
Darbepoetin alfa is an erythropoiesis-stimulating agent. It activates the same erythropoietin receptor pathway as the natural hormone erythropoietin, which normally signals bone marrow to make red blood cells. Chronic kidney disease can reduce natural erythropoietin production, while chemotherapy can suppress red blood cell production. By stimulating erythropoiesis—the formation of red blood cells—darbepoetin alfa can gradually raise hemoglobin and reduce the need for red blood cell transfusions in appropriately selected patients.
How it is taken
Actorise 100 Injection is given by injection. Darbepoetin alfa can be administered subcutaneously, meaning under the skin, or intravenously, meaning into a vein; the appropriate route depends on the clinical situation. The dose and treatment interval must be individualized by the treating clinician according to the indication, hemoglobin response, and other clinical factors. Hemoglobin should be monitored during treatment, and iron status should be evaluated before and during therapy. The pre-filled syringe should not be shaken.
Important warnings
Darbepoetin alfa and other ESAs can increase the risk of death, myocardial infarction, stroke, venous thromboembolism, and thrombosis of vascular access. In patients with chronic kidney disease, targeting hemoglobin above 11 g/dL with ESAs has been associated with increased cardiovascular and stroke risk. The medicine is contraindicated in uncontrolled hypertension, in patients who develop pure red cell aplasia after erythropoietin-protein treatment, and in those with a serious allergic reaction to darbepoetin alfa. Blood pressure should be controlled before and during therapy. Seizures, severe allergic reactions, severe skin reactions, and pure red cell aplasia can occur. In cancer, ESAs have been associated with shortened survival and/or increased tumor progression or recurrence in some studies, so their use is restricted to defined chemotherapy-associated anemia settings.
Side effects and monitoring
Common adverse effects reported with darbepoetin alfa in chronic kidney disease include high blood pressure, shortness of breath, peripheral swelling, cough, procedural low blood pressure, rash or redness, fluid overload, and vascular-access complications. Injection-site pain and seizures have also been reported. Serious risks include blood clots, heart attack, stroke, severe hypertension, seizures, serious allergic or severe skin reactions, and pure red cell aplasia. Seek urgent medical attention for chest pain, sudden weakness or numbness, difficulty breathing, symptoms of a serious allergic reaction, a seizure, or a severe skin reaction. Hemoglobin, blood pressure, treatment response, and iron status require monitoring; other causes of anemia should also be assessed if response is inadequate.
Pregnancy
Available human pregnancy data for darbepoetin alfa are insufficient to determine a drug-associated risk of major birth defects or miscarriage. Animal studies identified developmental effects at some exposures. The potential benefits and risks to the mother and fetus should therefore be considered when darbepoetin alfa is prescribed during pregnancy.
Breastfeeding
It is not known whether darbepoetin alfa is present in human breast milk, affects a breastfed child, or affects milk production. The benefits of breastfeeding should be considered together with the mother's clinical need for treatment and any potential effects on the breastfed child.
Storage
Store refrigerated at 2°C to 8°C. Do not freeze or shake. Protect the medicine from light. Product-specific sources for Actorise also identify refrigerated storage at 2°C to 8°C and state that it should not be frozen.
Frequently asked questions
How long does darbepoetin alfa take to improve hemoglobin?
The response is gradual rather than immediate. Hemoglobin is monitored regularly after treatment starts and after dose changes so the prescriber can assess the response; darbepoetin alfa should not be used as a substitute for transfusion when anemia needs immediate correction.
Why might my hemoglobin not rise after darbepoetin alfa injections?
Several factors can reduce the response. Iron deficiency, vitamin deficiency, bleeding, inflammation, and other causes of anemia should be evaluated, and iron status should be checked before and during ESA treatment.
Do I need iron while receiving Actorise?
Some patients do. Iron status should be checked before and during darbepoetin alfa therapy, and supplemental iron may be required when iron stores are inadequate.
Why does my blood pressure need checking during treatment?
Darbepoetin alfa can cause or worsen hypertension. Uncontrolled hypertension is a contraindication, so blood pressure should be controlled before treatment and monitored while therapy continues.
Can Actorise cause blood clots or a stroke?
Yes, these are important known risks of erythropoiesis-stimulating agents. Darbepoetin alfa has been associated with increased risks of blood clots, stroke, heart attack, and other serious cardiovascular events, particularly when treatment produces excessively high hemoglobin levels.
Can Actorise be used for every type of cancer-related anemia?
No. Darbepoetin alfa has specific restrictions in cancer and is used for anemia caused by myelosuppressive chemotherapy only in appropriately selected patients. It is not indicated in several other cancer-treatment situations, including when chemotherapy is being given with curative intent.
How should Actorise 100 Injection be stored?
Keep it refrigerated at 2°C to 8°C, protected from light. Do not freeze or shake the syringe.
Will I need blood tests while using Actorise?
Yes. Hemoglobin should be monitored during treatment, and iron status should be assessed before and during therapy. Blood pressure and the overall response to treatment also require monitoring.
Sources
Medical information notice: This information does not replace advice from a qualified healthcare professional. Use prescription medicine only as directed by the prescriber and the approved product information.
| Packaging | Qty |
|---|---|
| Delivery Time | 6 To 15 days |
Related products
Combutol 800 Mg (Ethambutol)
Imiquad Cream 0.5% (Imiquimod)
Imuran 50 Mg (Azathioprine)
Loparin 40 Mg/0.4 ml (Enoxaparin)
Mucinac 600 Mg (N-acetylcysteine)
Mycobutol 1000 Mg (Ethambutol)
NuLife Chewettes 4 Mg (Nicotine Polacrilex Gum Usp)
Reviews
There are no reviews yet.